Ilumya's US sales challenges, higher R&D spending, and the growth prospects of Leqselvi and Unloxcyt remain key factors shaping brokerage views on Sun Pharma. Sun Pharma shares recover after a 2.8 per cent fall as Bernstein and HSBC retain bullish calls following the US MFN pricing agreement. Sun Pharma shares recover after a sharp fall as brokerages.